STUDYING ATRIAL FIBRILLATION ON THE BASIS OF THE “PROFILE” REGISTRY
https://doi.org/10.15829/1728-8800-2014-2-35-39
Abstract
Aim. To research the prevalence of atrial fibrillation (AF) and to compare the clinical characteristics of the patients to those without AF.
Material and methods. At the moment of cross-section the Profile Study included 671 patients with various cardiovascular diseases, those who consulted at the Preventive pharmacotherapy department of the Centre.
Results. AF was diagnosed in 99 patients (14,7%). There was no difference by gender with those without AF, but they were significantly older. There was no difference in prevalence of the common risk factors, ischemic heart disease and peripheral atherosclerotic disease. Anamnesis of cerebral stroke was more common for the AF group: 9,1% vs 2,8%. Anamnesis of stomach ulcer disease was also more prevalent in AF group: 9,1% vs 4,4%.
Conclusion. The section-study of patients included into Profile Registry showed typical clinical properties for AF and made it to compare with those found in other registries.
About the Authors
S. Yu. Martsevich
State Research Centre for Preventive Medicine. Moscow, Russia
Russian Federation
Russian Federation
A. R. Navasardian
State Research Centre for Preventive Medicine. Moscow, Russia
Russian Federation
Russian Federation
N. P. Kutishenko
State Research Centre for Preventive Medicine. Moscow, Russia
Russian Federation
Russian Federation
L. Yu. Drozdova
State Research Centre for Preventive Medicine. Moscow, Russia
Russian Federation
Russian Federation
A. V. Zakharova
State Research Centre for Preventive Medicine. Moscow, Russia
Russian Federation
Russian Federation
N. V. Kiseleva
State Research Centre for Preventive Medicine. Moscow, Russia
on behalf of the “PROFILE” Workgroup
Russian Federation
Russian Federation
References
1. Phillips SJ. Is atrial fibrillation an independent risk factor for stroke? Can J Neurol Sci. 1990 May; 17 (2): 163–8.
2. Kirchhof P, Auricchio A, Bax J. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007; 28 (22): 2803–17.
3. Stewart S, Hart CL, Hole DJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002 Oct 1; 113 (5): 359–64.
4. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010; 31 (8): 967–75.
5. Camm AJ, Breithardt G, Crijns H. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). JACC. 2011; 58 (5): 493–501.
6. Alam M, Bandeali SJ, Shahzad SA. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. Expert Rev Cardiovasc Ther. 2012; 10 (3): 283–91.
7. Nieuwlaat R, Capucci A, Camm AJ. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26 (22): 2422–34.
8. Martsevich SYu, Ginzburg ML, Kutishenko NP, et al. The LIS research (study of mortality among patients survived acute myocardial infarction in Lyubertsy district): a portrait of a diseased. Cardiovascular Therapy and Prevention 2011; 10 (6): 89–93. Russian (Марцевич С. Ю., Гинзбург М. Л., Кутишенко Н. П. и др. Исследование ЛИС (Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда): портрет заболевшего. Кардиоваскулярная терапия и профилактика 2011;10 (6):89–93).
9. Boytsov SA, Martsevich SYu, Ginzburg ML. Lyubertsy study on mortality rate in patients after сerebral stroke or transient ischemic attack (LIS-2). Design and medical treatment estimation. Ration Pharmacother Cardiol 2013; 9 (2): 114–22. Russian (Бойцов С. А., Марцевич С. Ю., Гинзбург М. Л. Люберецкое исследование смертности больных, перенесших мозговой инсульт или транзиторную ишемическую атаку (ЛИС-2). Дизайн и оценка лекарственной терапии. Рациональная фармакотерапия в кардиологии 2013; 9 (2): 114–22).
10. Мartsevich SYu, Gaysenok OV, Tripkosh SG. Real practice of statins use and its dependence on follow-up in the specialized medical centre in patients with high cardiovascular risk (accordingtothe PROFILE register). Ration Pharmacother Cardiol 2013; 9 (4); 362–7. Russian (Марцевич С. Ю., Гайсёнок О. В., Трипкош С. Г. и др. Реальная практика назначения статинов и её зависимость от наблюдения в специализированном медицинском центре у больных с высоким риском сердечно-сосудистых осложнений (по данным регистра ПРОФИЛЬ). Рациональная фармакотерапия в кардиологии. 2013; 9 (4); 362–7).
11. European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31: 2369–429.
12. Manesh RP, Kenneth WM, Jyotsna G, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011; 365: 883–91.
13. Boytsov SA, Yakushin SS, Martsevich SYu. Outpatient register of cardiovascular diseases in the Ryazan region (RECVASA): principal tasks, experience of development and first results. Rational Pharmacother Card 2013;9 (1):4–14. Russian (Бойцов С. А., Якушин C. С. Марцевич С. Ю. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской области (РЕКВАЗА): основные задачи, опыт создания и первые результаты. Рациональная фармако-терапия в кардиологии 2013; 9 (1): 4–14.
14. Martsevich SYu, Gaysenok OV, Tripkosh SG. Medical supervision in specialized center and the quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFIL register). Ration Pharmacother Cardiol. 2013;9 (2):133–7. (Марцевич С. Ю., Гайсёнок О. В., Трипкош С. Г. Наблюдение в специализированном медицинском центре и качество гиполипидемической терапии у пациентов с сердечно-сосудистыми заболеваниями (по данным регистра ПРОФИЛЬ). Рациональная фармакотерапия в кардиологии. 2013; 9 (2); 133–7).
15. Ruff CT, Bhatt DL, Steg PG. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014; 170 (3): 413–8.
16. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000; 95: 2218–24.
Review
For citations:
Martsevich S.Yu., Navasardian A.R., Kutishenko N.P., Drozdova L.Yu., Zakharova A.V., Kiseleva N.V. STUDYING ATRIAL FIBRILLATION ON THE BASIS OF THE “PROFILE” REGISTRY. Cardiovascular Therapy and Prevention. 2014;13(2):35-39. (In Russ.) https://doi.org/10.15829/1728-8800-2014-2-35-39
Views:
1238
Email this article 
